Avecho Biotechnology (AVE) Stock Overview
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
AVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Avecho Biotechnology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.012 |
| 52 Week High | AU$0.012 |
| 52 Week Low | AU$0.003 |
| Beta | 0.91 |
| 1 Month Change | 33.33% |
| 3 Month Change | 50.00% |
| 1 Year Change | 100.00% |
| 3 Year Change | 33.33% |
| 5 Year Change | -45.45% |
| Change since IPO | -97.50% |
Recent News & Updates
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08
Shareholder Returns
| AVE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 33.3% | -5.1% | -2.6% |
| 1Y | 100.0% | -16.8% | 9.7% |
Return vs Industry: AVE exceeded the Australian Pharmaceuticals industry which returned -16.8% over the past year.
Return vs Market: AVE exceeded the Australian Market which returned 9.7% over the past year.
Price Volatility
| AVE volatility | |
|---|---|
| AVE Average Weekly Movement | 16.2% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.9% |
Stable Share Price: AVE's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: AVE's weekly volatility has decreased from 24% to 16% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | n/a | Paul Gavin | avecho.com.au |
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery.
Avecho Biotechnology Limited Fundamentals Summary
| AVE fundamental statistics | |
|---|---|
| Market cap | AU$44.08m |
| Earnings (TTM) | -AU$4.42m |
| Revenue (TTM) | AU$1.24m |
Is AVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVE income statement (TTM) | |
|---|---|
| Revenue | AU$1.24m |
| Cost of Revenue | AU$349.39k |
| Gross Profit | AU$888.38k |
| Other Expenses | AU$5.30m |
| Earnings | -AU$4.42m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0012 |
| Gross Margin | 71.77% |
| Net Profit Margin | -356.82% |
| Debt/Equity Ratio | 0% |
How did AVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 15:31 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avecho Biotechnology Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Stanton | Nomura Securities Co. Ltd. |